In Science this week: researchers engineer tobacco plant to produce chemotherapy precursor, predicting patient response to immunotherapy difficult, and more.
The researchers combined CRISPR knockouts with RNAi screening to overcome key limitations in using the gene-silencing technology to identify new drug targets.
The company was established by a co-founder of Beeologics, which was developing RNAi treatments for bee diseases before its acquisition by Monsanto.
In PLOS this week: gauging species divergence time, differentially expressed genes in female mosquitos during reproduction, and more.
Researchers used RNA interference and automated trait analyses to systematically track phenotypes in Caenorhabditis elegans worms from two genetic backgrounds.
In the study, the scientists used RNAi screening, whole-exome sequencing, and affinity proteomics to identify genes involved in cilia formation, as well as disease-causing defects.
Seth Bordenstein of Vanderbilt University will use the award to find genes that respond to inherited bacterial infections in insects.
The findings further point to the importance of the stability and dosage of RNAi molecules to gene silencing in environmental RNAi-sensitive insects.
The study is being conducted in Sierra Leone by the University of Oxford.
The drug is designed to silence complement component C5, whose loss is associated with an attenuated immune response against certain infections.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.